SCHEMBL2602741

SCHEMBL2602741

O=C(/C=C/c1ccc(O)c(O)c1)OCCCc1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 11/20 0.85
AKR1B10 O60218 5/20 0.85
AKR1B1 P15121 5/20 0.85
TTR P02766 4/20 0.85
CYP3A4 P08684 2/20 0.85
ALOX15 P16050 2/20 0.85
ALOX12 P18054 2/20 0.85
MAPK1 P28482 2/20 0.85
HSD17B10 Q99714 2/20 0.85
ALOX5 P09917 2/20 0.85
KDM4E B2RXH2 1/20 0.85
MEN1 O00255 1/20 0.85
GMNN O75496 1/20 0.85
ALDH1A1 P00352 1/20 0.85
EGFR P00533 1/20 0.85
LMNA P02545 1/20 0.85
ESR1 P03372 1/20 0.85
ERBB2 P04626 1/20 0.85
LCK P06239 1/20 0.85
FYN P06241 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20604716 0.96 APP (0.83) APPAKR1B10AKR1B1TTRCYP3A4
SCHEMBL19359013 0.95 APP (0.81) APPAKR1B10AKR1B1TTRCYP3A4
SCHEMBL19369291 0.95 APP (0.81) APPAKR1B10AKR1B1TTRCYP3A4
SCHEMBL20914979 0.95 APP (0.81) APPAKR1B10AKR1B1TTRCYP3A4
SCHEMBL20604718 0.95 APP (0.81) APPAKR1B10AKR1B1TTRCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL30070826 0.92 AKR1B10 (1.00) APPAKR1B10AKR1B1TTRCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL93649 0.92 AKR1B10 (1.00) APPAKR1B10AKR1B1TTRCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL28294426 0.92 AKR1B10 (1.00) APPAKR1B10AKR1B1TTRCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL490546 0.92 AKR1B10 (1.00) APPAKR1B10AKR1B1TTRCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL30695557 0.91 TTR (0.97) APPAKR1B10AKR1B1TTRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605352-B2 Compositions and methods for inhibiting blood cancer cell growth THE UNIVERSITY OF NEW BRUNSWICK (CA) 2026-04-21 US claimed
US-20240425441-A9 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ICOSA PHARMA INC. (CA) 2024-12-26 US claimed
US-20230391711-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-12-07 US claimed
EP-3423429-B1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-07-12 EP claimed
US-20220211653-A1 COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH THE UNIVERSITY OF NEW BRUNSWICK (CA) 2022-07-07 US claimed
EP-3955911-A1 COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH University of New Brunswick (CA) 2022-02-23 EP claimed
WO-2020210920-A1 COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH UNIVERSITY OF NEW BRUNSWICK (CA) 2020-10-22 WO claimed
US-20190119194-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIVERSITE DE MONCTON (CA) 2019-04-25 US claimed
US-12605352-B2 Compositions and methods for inhibiting blood cancer cell growth THE UNIVERSITY OF NEW BRUNSWICK (CA) 2026-04-21 US disclosed
US-12605352-B2 Compositions and methods for inhibiting blood cancer cell growth THE UNIVERSITY OF NEW BRUNSWICK (CA) 2026-04-21 US disclosed
US-20240425441-A9 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ICOSA PHARMA INC. (CA) 2024-12-26 US disclosed
US-20230391711-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-12-07 US disclosed
EP-4276089-A2 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY Universite De Moncton (CA) 2023-11-15 EP disclosed
EP-4276089-A2 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY Universite De Moncton (CA) 2023-11-15 EP disclosed
US-20120129931-A1 CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY Chemigen (US) 2012-05-24 US disclosed
US-20120100122-A1 COMBINATION THERAPY Chemigen (US) 2012-04-26 US disclosed
US-20120100122-A1 COMBINATION THERAPY Chemigen (US) 2012-04-26 US disclosed
WO-2012054446-A2 COMBINATION THERAPY Chemigen (US) 2012-04-26 WO disclosed
US-20080167277-A1 METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS MOLECULIN, L.L.C. 2008-07-10 US disclosed
US-20080167277-A1 METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS MOLECULIN, L.L.C. 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220211653-A1 COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH MCL1, BCL9, HCLS1 APP 4643/4885AKR1B10 3265/4885AKR1B1 4104/4885
US-20080167277-A1 METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS CYP24A1, VDR, CYP2R1 APP 1238/4885AKR1B10 2192/4885AKR1B1 1890/4885
US-20240425441-A9 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ALOX12, ALOX15B, ALOX5 APP 3143/4885AKR1B10 392/4885AKR1B1 182/4885
US-20190119194-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ALOX12, ALOX15B, ALOX5 APP 3143/4885AKR1B10 392/4885AKR1B1 182/4885
US-20230391711-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ALOX12, ALOX15B, ALOX5 APP 3143/4885AKR1B10 392/4885AKR1B1 182/4885
US-20120129931-A1 CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY CCAR2, BDNF, CASP3 APP 1097/4885AKR1B10 4586/4885AKR1B1 4466/4885
US-12605352-B2 Compositions and methods for inhibiting blood cancer cell growth MCL1, HRH2, SLC25A11 APP 4725/4885AKR1B10 2410/4885AKR1B1 2335/4885
US-20120100122-A1 COMBINATION THERAPY SLC25A20, TFAM, NDUFAB1 APP 551/4885AKR1B10 1036/4885AKR1B1 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.